LifeSci Capital Reaffirms Their Hold Rating on Repare Therapeutics (RPTX)
In a report released today, Charles Zhu from LifeSci Capital maintained a Hold rating on Repare Therapeutics (RPTX – Research Report). The ...
Protara Therapeutics (TARA) Has a New Rating from LifeSci Capital
In a report released today, Charles Zhu from LifeSci Capital initiated coverage with a Buy rating on Protara Therapeutics (TARA – Research ...
Business Insider26d
Zymeworks (ZYME) Receives a Buy from LifeSci Capital
In a report released today, Charles Zhu from LifeSci Capital initiated coverage with a Buy rating on Zymeworks (ZYME – Research Report) and a price target of $30.00. The company’s shares ...
LifeSci Capital Initiates a Buy Rating on Zymeworks (ZYME)
LifeSci Capital analyst Charles Zhu initiated coverage with a Buy rating on Zymeworks (ZYME – Research Report) today and set a price target of ...
Business Insider27d
Analysts Are Bullish on These Healthcare Stocks: Mersana Therapeutics (MRSN), Revelation Biosciences (REVB)
Mersana Therapeutics (MRSN) LifeSci Capital analyst Charles Zhu reiterated a Buy rating on Mersana Therapeutics on March 8 and set a price target of $3.00. The company’s shares closed last ...
Business Insider1mon
LifeSci Capital Remains a Hold on Repare Therapeutics (RPTX)
In a report released yesterday, Charles Zhu from LifeSci Capital maintained a Hold rating on Repare Therapeutics (RPTX – Research Report). The company’s shares closed yesterday at $1.29.
Business Insider1mon
LifeSci Capital Sticks to Its Hold Rating for Repare Therapeutics (RPTX)
LifeSci Capital analyst Charles Zhu maintained a Hold rating on Repare Therapeutics (RPTX – Research Report) today. The company’s shares opened today at $1.17. See what stocks are receiving ...